(Reuters) — A U.S. judge said Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan (NYSE: AGN) before making an unsuccessful takeover bid for the maker of Botox. In a Nov. 9 decision, U.S. District Judge David Carter in Santa Ana, Calif., […]
Pershing Square Capital Management
Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014
MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A
Ackman supports Allergan’s $66B sale to Actavis
UPDATE: Actavis trumps Valeant with $66B offer for Allergan
Source: Allergan near $66B buyout to escape Valeant, Ackman
Report: Actavis may buy Allergan for at least $60 billion
Medtronic inks package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien | The week in medtech M&A
Salix inventory snafu sinks deal with Allergan
Allergan in talks with 3rd-party acquirer
Court leaves door open for Ackman’s vote at Allergan meeting
Ackman (Reuters/Eduardo Munoz).
Click to enlarge.
